Conference · Medicine & Health
Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...
In short
Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026 was a conference on medicine & health held in Madrid, Spain, from 23–27 Oct 2026.

About this event
SHANGHAI and HONG KONG, July 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that two clinical abstracts featuring the latest results from the Phase II study of Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 and the Phase Ib/II study of oral CD73 small-molecule inhibitor ATG-037 have been accepted for poster presentation at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026), taking place from October 23rd to October 27th, 2026, at the IFEMA MADRID Convention Center in Madrid, Spain.
ATG-022 (Claudin 18.2 Antibody-Drug Conjugate) Title: ATG-022, a Claudin 18.2 ADC, in Advanced Gastric and Gastroesophageal Junction Cancer (CLINCH): Phase 2 Results Presentation Number: 2886P Date: October 25, 2026 Time: 12:00PM-12:45PM (Central European Time) 7:00PM-7:45PM (Beijing Time)
ATG-037 (Oral CD73 Small Molecule Inhibitor) Title: Efficacy and safety of ATG-037, an oral CD73 inhibitor, plus pembrolizumab in patients with checkpoint inhibitor (CPI) resistant melanoma: Updated results from the STAMINA-01 trial Presentation Number: 2087P Date: October 24, 2026 Time: 12:00PM-12:45PM (Central European Time) 6:00PM-6:45PM (Beijing Time)
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager® platform.
Keywords
Quick answers
When is Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026?
It took place from 23–27 Oct 2026.
Where is Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026 held?
In Madrid, Spain.
Listed by the organizer on 5 Nov 2026, last updated . Check dates and fees on the official website before booking travel. Report a problem with this listing.